Navigation Links
Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
Date:4/8/2008

SOUTH SAN FRANCISCO, Calif., April 8, 2008 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer announced today that it has entered into an agreement with Monogram Biosciences, Inc., under which Monogram will evaluate selected Raven monoclonal antibodies for use with its VeraTag(TM) technology for diagnosis of cancer.

"Raven's extensive library of antibody candidates that bind to antigens present at high levels on tumor tissue can be developed as therapeutic and diagnostic antibodies," stated George Schreiner, M.D., Ph.D., chief executive officer of Raven biotechnologies. "Through our collaboration with Monogram we hope ultimately to accelerate the development of targeted oncology therapeutics."

The Raven technology platform has generated well-characterized, high-affinity monoclonal antibodies to proteins on the cell surface that can be used to quickly identify and validate targets. The platform has delivered an extensive library of antibodies targeting novel and recognized antigens. Raven is initially focusing on antibody-based therapeutics targeting lung, colon, pancreatic, prostate, breast, and ovarian cancer.

Monogram Biosciences' VeraTag(TM) technology can accelerate the development of targeted therapeutics, improve clinical trial design and results, clarify and individualize the selection of medications, and optimize outcomes for patients with cancer and other serious diseases.

About Raven biotechnologies

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast and ovarian cancer.


'/>"/>
SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
2. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
3. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
6. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
7. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
8. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
9. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
10. VaxGen and Raven Terminate Merger Agreement
11. Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... OAI, a leading Silicon Valley, ... Industries, announces the new Model 800E front and backside, semi-automatic mask aligner system. ... aligners. OAI has already received and installed several orders for the ...
(Date:8/17/2017)... CA (PRWEB) , ... August 17, 2017 , ... ... for cancer research and personalized medicine, today announced the launch of a new ... City, Missouri. The study’s goal is to evaluate the potential for early detection ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... Electrospraying line of nanofiber and nanoparticle fabrication instruments from Bioinicia. ... to fully automated pilot plants and equipment for industrial manufacturing. All equipment ...
(Date:8/16/2017)... ... ... While art and science are often thought of as two completely separate modes ... Mesh Is Also a Snare, a group exhibition presented by the Philadelphia-based artist collective ... on August 17 and run through September 30. An opening reception will be held ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
Breaking Biology News(10 mins):